EC Number   |
Inhibitors  |
Structure |
|---|
   3.4.21.7 | RG1503 |
- |
 |
| 3.4.21.7 | SB203580 |
inhibits plasmin-induced TNF-alpha release by 75% and IL-6 release by 79% |
  |
| 3.4.21.7 | serpinb2 |
steroid-treated ovariectomized mice deficient in tissue inhibitor of metalloprotease-1 and exposed to estrogen show a significant increase in plasmin activity. Increase is probably due to reduced expression of plasmin inhibitors serpinb7 and serpinb2 |
|
| 3.4.21.7 | serpinb7 |
steroid-treated ovariectomized mice deficient in tissue inhibitor of metalloprotease-1 and exposed to estrogen show a significant increase in plasmin activity. Increase is probably due to reduced expression of plasmin inhibitors serpinb7 and serpinb2. Serpinb7 is localized to luminal and glandular epithelial cells of the uterus. Expression of serpinb7 is decreased by estrogen and shows an inverse relationship with plasmin activity |
|
| 3.4.21.7 | sodium 2,6-diformyl-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate |
about 93% residual activity at 0.4 mM |
|
| 3.4.21.7 | sodium 3-(3-[[1-(4-[2-[3-(acetyloxy)phenyl]-4-oxoquinazolin-3(4H)-yl]butyl)-1H-1,2,3-triazol-4-yl]methyl]-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl sulfate |
about 55% residual activity at 0.4 mM |
|
| 3.4.21.7 | Soybean trypsin inhibitor |
- |
|
| 3.4.21.7 | stearate |
- |
|
| 3.4.21.7 | streptokinase |
- |
|
| 3.4.21.7 | sucrose octasulfate |
about 99% residual activity at 0.4 mM |
|
